Revised SPCs: Tivicay (dolutegravir sodium) Film-Coated Tablets – all strengths

Dolutegravir must now not be administered concurrently with medicinal products with narrow therapeutic windows that are substrates of organic cation transporter 2, including but not limited to fampridine.

SPS commentary:

This applies to all dolutegravir sodium medicinal products; SPCs are expected to update in accordance.

electronic Medicines compendium